Landos Biopharma — Company Overview, News & Financial Data

Landos Biopharma (NASDAQ:LABP) specializes in the development of innovative oral therapeutics for patients with autoimmune diseases. With a focus on leveraging its proprietary LANCE platform, Landos aims to discover and advance a new wave of medicines targeting the LANCL2, NLRX1, and PLXNA4 pathways. These pathways have shown promise for their potential in managing complex conditions such as Crohn's disease, ulcerative colitis, and other autoimmune diseases, positioning Landos at the forefront of autoimmune therapy research and development. The company's mission revolves around improving patient outcomes and offering new, safer treatment alternatives that can make a significant difference in the lives of those suffering from chronic autoimmune conditions.